- Home
- OFS vs KRRO Comparison
OFS vs KRRO Comparison
Compare OFS & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFS | KRRO |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.7M | 58.6M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OFS | KRRO |
|---|---|---|
| Price | $4.55 | $8.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $74.17 |
| AVG Volume (30 Days) | 113.2K | ★ 354.2K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 14.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $42,970,000.00 | $7,371,000.00 |
| Revenue This Year | N/A | $144.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.08 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.44 | $5.20 |
| 52 Week High | $9.80 | $55.89 |
Technical Indicators
Market Signals| Indicator | OFS | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 34.27 | 36.12 |
| Support Level | $4.44 | $7.63 |
| Resistance Level | $4.66 | $8.54 |
| Average True Range (ATR) | 0.26 | 0.65 |
| MACD | -0.01 | 1.12 |
| Stochastic Oscillator | 17.20 | 80.00 |
Price Performance
Historical ComparisonAbout OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.